1 |
ClinicalTrials.gov (NCT03088878) A Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies. U.S.National Institutes of Health.
|
2 |
ClinicalTrials.gov (NCT05156905) A Phase 1b Trial Investigating Docetaxel Combined With Cirmtuzumab in Patients With Metastatic Castration Resistant Prostate Cancer. U.S.National Institutes of Health.
|
3 |
The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells. Pharmaceutics. 2022 Apr 11;14(4):837.
|
4 |
ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models. Blood. 2021 Jun 17;137(24):3365-3377.
|
5 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
6 |
Clinical pipeline report, company report or official report of VelosBio.
|
7 |
Clinical pipeline report, company report or official report of NBE-Therapeutics.
|
8 |
ClinicalTrials.gov (NCT02194374) Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)
|
9 |
ClinicalTrials.gov (NCT02706392) Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
|
|
|
|
|
|
|